# reload+after+2024-01-21 22:44:14.313571
address1§Baarerstrasse 14
city§Zug
zip§6300
country§Switzerland
phone§41 41 561 32 77
website§https://www.crisprtx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and VCTX211, an investigational, allogeneic, gene-edited, stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
fullTimeEmployees§458
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Samarth  Kulkarni Ph.D.', 'age': 44, 'title': 'CEO & Chairman', 'yearBorn': 1979, 'fiscalYear': 2022, 'totalPay': 1310000, 'exercisedValue': 10548686, 'unexercisedValue': 7970225}, {'maxAge': 1, 'name': 'Mr. James R. Kasinger', 'age': 51, 'title': 'General Counsel & Secretary', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 709250, 'exercisedValue': 0, 'unexercisedValue': 2530873}, {'maxAge': 1, 'name': 'Dr. Phuong Khanh Morrow FACP, M.D.', 'age': 49, 'title': 'Chief Medical Officer', 'yearBorn': 1974, 'fiscalYear': 2022, 'totalPay': 688258, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Shaun  Foy', 'title': 'Founder', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Emmanuelle Marie Charpentier', 'title': 'Co-Founder & Scientific Advisory Board Member', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Craig C. Mello Ph.D.', 'title': 'Scientific Founder & Advisory Board Member', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Chad A. Cowan Ph.D.', 'title': 'Scientific Founder', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Matthew  Porteus M.D., Ph.D.', 'age': 58, 'title': 'Scientific Founder & Advisory Board Member', 'yearBorn': 1965, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Daniel G. Anderson Ph.D.', 'title': 'Scientific Founder & Advisory Board Member', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Raju Yashaswi Prasad Ph.D.', 'age': 39, 'title': 'Chief Financial Officer', 'yearBorn': 1984, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§3
boardRisk§9
compensationRisk§10
shareHolderRightsRisk§2
overallRisk§8
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.722
priceToSalesTrailing12Months§28.347021
currency§USD
dateShortInterest§1702598400
forwardEps§-5.34
pegRatio§0.12
exchange§NGM
quoteType§EQUITY
shortName§CRISPR Therapeutics AG
longName§CRISPR Therapeutics AG
firstTradeDateEpochUtc§1476883800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§10230d3e-917c-3849-a2ff-4a032541eb82
gmtOffSetMilliseconds§-18000000
targetHighPrice§199.0
targetLowPrice§30.0
targetMeanPrice§84.46
targetMedianPrice§80.0
recommendationMean§2.4
recommendationKey§buy
numberOfAnalystOpinions§24
quickRatio§15.641
grossMargins§-2.01646
ebitdaMargins§-2.36979
trailingPegRatio§None
